Physicians who provide Veklury (remdesivir) for outpatient use can improve patient access to the COVID-19 therapeutic by volunteering their contact information to a Department of Health and Human Services (HHS) directory.
The agency has added outpatient Veklury to its COVID-19 Therapeutics Locator, an interactive mapping tool that assists in matching patients at high risk of severe COVID-19 to medications that can prevent the disease from progressing. Currently, the locator primarily tracks locations that offer Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir/ritonavir).
A 2022 study indicated that a three-day course of remdesivir greatly reduces the risk of hospitalization after a COVID-19 infection. However, as the drug must be administered intravenously for three consecutive days, outpatient access can be a challenge. The HHS initiative aims to improve visibility of sites that can provide remdesivir and thus bridge the potential gap of care.
The Texas Department of State Health Services encourages all eligible physicians to participate in HHS’ COVID-19 Therapeutics Locator. Sign-up is entirely voluntary, and only information provided by the infusion site will be displayed in the directory. HHS says the process requires minimal engagement: just location information and agreement to participate. Participating locations can opt out of displaying their information at any time.
To provide your information to the service, visit the Provider Opt-In for ASPR Therapeutics Public Locator. Direct your questions to HHS via email.
Last Updated On
April 04, 2023
Originally Published On
March 21, 2023